3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Conditions
Ovarian Neoplasms
15
Uterine Cervical Neoplasms
12
Carcinoma, Non-Small-Cell Lung
10
Melanoma
9
Triple Negative Breast Neoplasms
7
Endometrial Neoplasms
7
Stomach Neoplasms
6
Carcinoma, Transitional Cell
6
Carcinoma, Renal Cell
6
Squamous Cell Carcinoma of Head and Neck
5
Small Cell Lung Carcinoma
5
Fallopian Tube Neoplasms
5
Colorectal Neoplasms
4
Carcinoma, Merkel Cell
4
Carcinoma, Hepatocellular
4
Neoplasm Metastasis
3
Mesothelioma
3
Esophageal Neoplasms
3
Cholangiocarcinoma
3
Vulvar Neoplasms
2
Urinary Bladder Neoplasms
2
Seminoma
2
Sarcoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Nasopharyngeal Carcinoma
2
Lung Neoplasms
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Acute
2
Interventions
sarcolipin
1
TP protocol
1
Positron Emission Tomography Computed Tomography
1
Nivolumab
1
Lymph Node Excision
1
Ipilimumab
1
Drug Therapy
1
Diffusion Magnetic Resonance Imaging
1
Cytoreduction Surgical Procedures
1
Cisplatin
1
Chemoradiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphatic Metastasis
×
Ipilimumab
×
Gynecologic
×
Clear all
NCT05504642
2023-04-18
CERAD-IMMUNE
Universitätsklinikum Köln
Phase 2
Withdrawn